Date:11/12/2009

7,147,701 7,365,765 Total Assets $37,073,864 $28,997,639 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued expenses $2,446,257 $2,191,976 Customer and other deposits 105,066 2,592,250 Value-added tax payable 1,000,837 527,103 Income tax payable 988,791 413,205 Total Current Liabilities 4,540,951 5,724,534 Commitment Stockholders' Equity Series A, convertible preferred stock, $0.001 par value, 5,000,000 shares authorized, None issued and outstanding -- -- Undesignated preferred stock, $.001 par value, 5,000,000 shares authorized, None issued and outstanding -- -- Common stock, $.001 par value, 100,000,000 shares authorized, 23,240,899 shares issued and outstanding at September 30, 2009 and December 31, 2008 23,241 23,241 Additional paid-in capital 10,430,168 10,430,168 Statutory reserves 2,487,480 1,585,383 Retained earnings 18,904,913 10,996,655 Accumulated other comprehensive income 687,111 237,658 Total Stockholders' Equity 32,532,913 23,273,105 Total Liabilities and Stockholders' Equity $37,073,864 $28,997,639 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended Nine Months Ended September 30, September 30, 2009 2008
'/>"/>

SOURCE Biostar Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Biostar Pharmaceuticals, Inc. Receives the Chinese Military Drug Administration Clearance to Begin Clinical Trial for Zushima Analgesic Aerosol Spray
2. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
3. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
5. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
6. BioMarin Acquires Huxley Pharmaceuticals, Inc.
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
8. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
9. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
10. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
11. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.